Crescent Biopharma, Inc. (CBIO)

Every figure this model derived for CBIO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 939,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 171,593,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 179,006,000 AssetsCurrent 2026-06-30
current liabilities 18,537,000 LiabilitiesCurrent 2026-06-30
equity 163,255,000 StockholdersEquity 2026-06-30
interest expense 0 InterestExpenseNonoperating 2026-06-30
ocf -72,679,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 10,844,000 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 14,809,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CBIO on one particular measure came for.

RatioValue
cash operating margin-1415.06
current ratio11.61
current ratio reported9.66
dilution pct1.79
fcf margin-678.88
growth cv1.33
operating margin-1553.58
owner earnings margin-815.45
sbc pct revenue136.56

What to be careful about

What this model itself distrusts about CBIO's figures. Written by the derivation as it ran, not added afterwards.